PDF
Summary of NACI Updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
Organization: Public Health Agency of Canada (PHAC)Published: 2022
This document provides a summary of recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults.
Resource Group:
Implementation Tool
Product Type: Guide
Vaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Promotion and Communication
Marketing and Campaigns
Product Type: Guide
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Promotion and Communication,Marketing and Campaigns Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Promotion and Communication
Marketing and Campaigns
Language:
English
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.